Cosmetic Study of AO+Mist in Improving the Appearance of Skin Afflicted With Keratosis Pilaris

This will be a single center, double-blind, placebo-controlled study in subjects with
keratosis pilaris affecting both sides of the body.

Subjects will be screened within 4 weeks of enrollment. Subjects will be seen at the research
facility on for the baseline visit and will be asked to return to the site on weeks 1, 2, 3
and 4 for assessments. Test product application will occur for four weeks starting with the
day of the baseline visit.

Inclusion Criteria:

1. Male and female subjects ≥18 and ≤65 years of age

2. Subject is in good general health

3. Diagnosis of keratosis pilaris involving areas of the body affected bilaterally

4. Subject has Fitzpatrick Skin Type I-VI

5. Willing to refrain from using any treatments, other than the investigational product,
including antibiotics, for acne present on the face.

6. Ability to comprehend and comply with procedures

7. Agree to commit to participate in the current protocol

8. Provide written informed consent prior to any study procedure being performed (all
subjects should be able to understand the informed consent form and any other
documents that subjects are required to read)

Exclusion Criteria:

1. Male and female subjects under 18 years or over 65 years of age

2. Female subjects who are pregnant or lactating

3. Subjects who have received laser therapy to the KP affected area in the past 1 year

4. Subjects with a concurrent diagnosis of another skin condition or malignancy

5. Subjects with tan or sunburn over the area affected by KPin the past month

6. Subjects with open, non-healing sores or infections at any skin site

7. Treatment with over-the-counter topical medications for the treatment of acne vulgaris
including benzoyl peroxide, topical anti-inflammatory medications, corticosteroids,
α-hydroxy/glycolic acid, including lactic acid lotions (Am-Lactin, Lac-Hydrin), urea
cream (Carmol 10, Carmol 20, Carmol 40, Urix 40), salicylic acid (Salex lotion),
topical corticosteroids within 4 weeks prior to baseline.

8. Treatment with systemic corticosteroids (including intranasal and inhaled
corticosteroids) within 4 weeks prior to baseline

9. Treatment with systemic antibiotics or systemic anti-acne drugs or systemic
anti-inflammatory drugs within 4 weeks prior to baseline

10. Prescription topical retinoid use on the face or body within 4 weeks of baseline
(e.g., tretinoin, tazarotene, adapalene).

11. Oral retinoid use (e.g., isotretinoin) within 12 months prior to baseline or vitamin A
supplements greater than 10,000 units/day within 6 months of baseline..

12. Treatment with any investigational drug within 30 days prior to the beginning of the
screening period (this includes investigational formulations of marketed products,
inhaled and topical drugs)

13. Subjects who are unable to understand the protocol or give informed consent

14. Any other condition and/or situation that causes the Investigator to deem a subject
unsuitable for the study (e.g., due to expected study medication non-compliance,
inability to medically tolerate the study procedures, or a subject's unwillingness to
comply with study-related procedures)